About 9 in 10 children referred for ADHD or autism had elevated symptoms in at least 2 of 4 areas — ADHD, autism, defiance and learning problems — and the same overlap showed up in ordinary community children at lower rates, according to a 2026 Pennsylvania study based on mothers’ ratings.1 Research Highlights Overlap was …
Adults with type 2 diabetes who also had ADHD died at a higher rate than those without ADHD in a 2026 study of 1.9 million adults newly diagnosed with diabetes across 7 countries. They did not, however, have more heart attacks, strokes or cardiovascular deaths.1 Research Highlights Higher death rate with ADHD: after adjusting for …
Guanfacine, a non-stimulant ADHD medication, reduced hyperactivity in autistic children in a placebo-controlled trial. A 2026 review argues it may also steady prefrontal brain signaling and calm the brain’s immune cells, but that immune effect has never been tested with guanfacine itself.1 Research Highlights Hyperactivity fell in the largest autism trial: in 62 autistic children, …
Among broad child behavior questionnaires used to screen for ADHD, the short hyperactivity-inattention subscale of the Strengths and Difficulties Questionnaire (SDQ) has the strongest measurement evidence, according to a 2026 review of 36 studies. None of the 12 scales reviewed met every quality standard.1 Research Highlights 36 studies, 12 scales: a systematic review in BMC …
A 2026 meta-analysis of 50 studies estimated that about 1 in 3 people with neurofibromatosis type 1 (NF1) have ADHD (33%), and that roughly 1 in 10 have autism (11%), seizures (11%), depression (13%), or anxiety (12%).1 Every one of those figures sits well above typical population rates, but the individual studies disagreed so widely …
A 2025 scoping review of 292 adult ADHD randomized controlled trials found that 49.7% allocated diagnosis without a general psychopathology assessment, and only 35% reported that psychiatrists or psychologists assigned the ADHD diagnosis. Research Highlights 292 adult ADHD RCTs were reviewed: Studart et al. screened 706 PubMed records and included 292 randomized controlled studies.1 49.7% …
A 2026 medRxiv preprint using parent-cocreated sensory-related outcome measures found that 83% of children and teens improved on at least 1 PROMIS domain during 6 months of bumetanide treatment.1 The result is interesting, but the unmasked single-case design means the strongest claim is about sensitive outcome tracking, not definitive bumetanide efficacy. Research Highlights Most participants …